Full-Time
Executive Director
Portfolio Analytics & Systems Architecture
Posted on 9/8/2026
Dyne Therapeutics
201-500 employees
Develops muscle-disease therapies using FORCE platform
Compensation Overview
$249k - $305k/yr
Waltham, MA, USA
In Person
Bachelor's, Master's, MBA, PhD
 Data & Analytics |
|---|
Get referred to Dyne Therapeutics
See people who can refer or advise you
- A bachelor's degree in a quantitative or life sciences field such as Statistics, Data Science, Engineering, Operations Research, Epidemiology, Pharmacy, or Biology.
- At least 18 years of increasing responsibility in biopharma or biotechnology research and development, focused on clinical operations analytics, portfolio management, or development operations, including at least 5 years leading multidisciplinary teams.
- A proven track record building enterprise data and analytics platforms and single-source-of-truth solutions for research and development portfolios, integrating internal and external or vendor data such as contract research organization feeds and benchmarks.
- Demonstrated expertise with portfolio, program, and study key performance indicators, operational planning, planned-versus-actual analysis, and scenario modeling for timelines, costs, risks, and resources.
- Hands-on experience with advanced analytics and machine learning, including forecasting, simulation, and optimization, and turning algorithms into operational tools that drive business decisions.
- A strong understanding of the clinical development lifecycle, including feasibility, site activation, enrollment, data management, monitoring, and close-out, along with familiarity with Good Clinical Practice, Good Practice requirements, data privacy, and validation expectations for decision-support tools.
- The ability to influence senior stakeholders, translate complex analytics into clear narratives, and drive enterprise alignment.
- The ability to partner effectively with senior leaders to advance company and portfolio objectives.
- The ability to influence without direct authority across all organizational levels, including senior functional leaders.
- Strong verbal and written communication skills, including the ability to convey complex information clearly to diverse audiences in written, verbal, and presentation formats.
- The ability to interpret and communicate complex data to diverse audiences.
- The ability to work in a matrix environment.
- The ability to work independently as a hands-on manager and proactively contribute as a resource when necessary.
- Flexibility to adapt to changing and growing customer needs.
- A high level of integrity, compliance, ethics, and transparency.
- Design, define, and advance a next-generation insights platform that provides trusted, real-time reporting and analytics across studies, programs, and the portfolio, supporting monitoring of time, cost, and quality and decision-making from study teams through the Executive Committee and Board.
- Establish and govern a single source of truth by integrating internal and external operational data, including contract research organization and vendor feeds and benchmarking sources, into a harmonized model with data quality, lineage, and access controls.
- Serve as the primary technology leader and business partner to Portfolio and Program Management and Clinical for data, portfolio and analytics systems, and clinical systems architecture and operations.
- Architect a centralized operational data infrastructure, such as a data lake or warehouse, semantic layer, and data products, in partnership with Information Technology and Digital teams.
- Integrate operational planning data, including study and program plans, budgets, and baselines, with actuals to enable planned-versus-actual comparisons for timelines and costs.
- Implement scalable operational data governance, including metadata, master data, and standards, aligned with research and development operating models and Good Practice expectations.
- Serve as the primary Information Technology liaison for Portfolio and Analytics teams and clinical and research and development teams, translating business needs into actionable technology solutions.
- Lead the delivery, support, and continuous improvement of business technology platforms, including portfolio management tools, clinical systems, and portfolio and analytics tools.
- Develop standard analytical frameworks and methodologies, including definitions, metric specifications, and visualization standards, to drive consistency and comparability.
- Define and operationalize clinical study, program, and portfolio key performance indicators and performance analytics.
- Lead the creation of advanced analytics and simulation capabilities to predict and optimize development timelines, costs, and risks, including slippage forecasting, patient enrollment trajectories, budget risks, and operational risks.
- Design and deploy prescriptive analytics powered by artificial intelligence and machine learning to anticipate challenges and provide actionable recommendations.
- Enable portfolio-wide scenario modeling and resource planning for governance decisions involving starts, stops, sequencing, trade-offs, capacity constraints, and resource supply.
- Develop predictive country and site selection analytics to optimize trial delivery and inform feasibility and country footprint decisions.
- Establish a study-level insights platform using structured operational data to provide site- and principal-investigator-level insights on enrollment health, quality, cost, and competitive trial density.
- Design and institutionalize integrated resource management that analyzes resource demand versus actuals, predicts artificial-intelligence-enabled resource demand, and identifies capacity bottlenecks in partnership with Human Resources and functional leaders.
- Drive change management and adoption of analytics capabilities by embedding insights into governance reviews, quarterly business reviews, portfolio prioritization, and study health checks.
- Embed regulatory compliance, including Good Practice requirements and the General Data Protection Regulation, into solutions and safeguard company data.
- Identify emerging technologies that can elevate research and development capabilities and portfolio management and operational insights strategies.
- Develop ideas that challenge the status quo and deliver measurable business impact.
- A master's or PhD degree in Data Science, Biostatistics, Operations Research, or a related discipline.
- An MBA.
- Experience with site and country selection analytics, enrollment prediction, and vendor performance analytics.
- Familiarity with research and development systems such as clinical trial management systems, electronic data capture, electronic trial master files, randomization and trial supply management, safety systems, and electronic clinical outcome assessments.
- Familiarity with portfolio and financial planning, including enterprise planning tools, and Human Resources capacity planning.
- A background in data governance, including metadata and master data management, data product management, and adoption at scale.
Dyne Therapeutics develops therapies for serious muscle diseases using its FORCE™ platform, which helps deliver oligonucleotide medicines to muscle tissue. Through a portfolio of experimental therapies, the company advances them in clinical trials (ACHIEVE and DELIVER) with the aim of treating rare muscle diseases. The product works by enhancing targeted delivery of oligonucleotides to muscle, enabling existing genetic medicines to reach affected tissues more effectively. Dyne differentiates itself by its proprietary FORCE™ technology and its focus on rare muscle diseases, positioning itself for growth as trials progress toward potential commercialization. The company’s goal is to bring effective treatments to patients and families affected by serious muscle diseases, expanding options as its therapies advance through development and, potentially, regulatory approval.
Company Size
201-500
Company Stage
IPO
Headquarters
Waltham, Massachusetts
Founded
2017
Get referred to Dyne Therapeutics
See people who can refer or advise you
Simplify's Take
What believers are saying
- Dyne ended June 30, 2026 with $898.5 million cash and July equity proceeds.
- ACHIEVE enrolled 71 participants in June 2026; HARMONIA dosing began July 2026.
- FDA granted Priority Review for z-rostudirsen July 20, 2026, signaling regulatory momentum.
What critics are saying
- Sarepta's Exondys 51 and gene-therapy franchise defend exon-51 patients before January 2027.
- If z-rostudirsen misses approval, Dyne stays pre-revenue and financing resets by 2028.
- June 30, 2026 net loss hit $178.6 million, pressuring execution across three programs.
What makes Dyne Therapeutics unique
- FORCE™ targets muscle delivery, pairing oligonucleotides with tissue-specific uptake, not broad systemic exposure.
- Zeleciment rostudirsen's January 21, 2027 PDUFA is first-in-class commercialization for Dyne.
- Dyne spans DMD, DM1, and FSHD, creating multiple shots on muscle-disease biology.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Remote Work Options
Growth & Insights and Company News
6 month growth
↓ -1%1 year growth
↑ 0%2 year growth
↓ -1%Dyne Therapeutics shares dropped 31% to $16.76 in premarket trading on Tuesday, with no official company announcement explaining the decline. The biotechnology firm is developing treatments for neuromuscular diseases, including z-rostudirsen for Duchenne muscular dystrophy, which has a regulatory decision date of 21 January 2027. The company recently reported a quarterly net loss of $178.6 million, or $1.08 per share, missing consensus estimates of $0.75 per share. The sharp decline stood in contrast to broader market moves, with the S&P 500 down 0.3% and the Nasdaq slipping 0.1% during the same period. No new clinical or regulatory developments were confirmed to explain the trading movement.
Dyne Therapeutics has commenced an underwritten public offering of $300 million of its common stock. The clinical-stage company, which focuses on treatments for genetically driven neuromuscular diseases, also plans to grant underwriters a 30-day option to purchase up to an additional $45 million of shares. Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the offering. LifeSci Capital and Raymond James are also serving as joint book-running managers, whilst Jones is acting as lead manager. The offering is being made pursuant to a shelf registration statement filed with the Securities and Exchange Commission on 5 March 2024. The company is currently developing clinical programmes for myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Dyne gets early 2027 decision date for Duchenne therapy, analysts expect 'smooth' review. July 21, 2026 | If approved, Dyne Therapeutics' zeleciment rostudirsen could "capture the majority" of the exon-51 Duchenne muscular dystrophy market, given its better efficacy and dosing profile versus Sarepta Therapeutics' exon-skipping therapy Exondys 51, the current standard of care, according to Oppenheimer. The FDA has accepted Dyne Therapeutics' application for its investigational Duchenne muscular dystrophy therapy, setting a target action date of Jan. 21, 2027. "We anticipate a smooth approval," Oppenheimer told investors in a note on Monday, adding that the therapy, dubbed zeleciment rostudirsen (z-rostudirsen) is poised to "capture the majority of market share," given stronger dystrophin benefits and a more convenient dosing profile than the current standard treatment. Outside of symptomatic management through corticosteroids, Sarepta Therapeutics' Exondys 51 is a standard of care regimen for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping. Dyne, however, could challenge Exondys with z-rostudirsen, which in the Phase 1/2 DELIVER trial outperformed Sarepta's asset, Jefferies said in a Monday note, adding that the early data cut looks "best-in-class." Exondys is dosed weekly, while z-rostudirsen is designed to be given once every four weeks - a "convenient" profile, the firm noted. Given its convenience and efficacy advantages, "z-rostudirsen could command a pricing premium" if approved, Jefferies continued. The analysts added that they expect uptake to be "robust" across three key patient subgroups: those who have yet to undergo Exondys treatment, those who have discontinued Sarepta's therapy and those who are currently receiving it. Dyne is seeking accelerated approval for z-rostudirsen in patients with DMD who are amenable to exon 51 skipping, according to a company release on Monday. Topline data from the registrational cohort of DELIVER, released December 2025, showed a 5.46% increase at six months in concentrations of the dystrophin protein, a key disease marker. Patients also saw improvements in key functional measures, including time-to-rise velocity and the 10-meter walk/run test. Lung function, a major driver of death in DMD, was preserved at six months. Dyne's exon-skipping therapy zeleciment rostudirsen resulted in an approximately sevenfold increase in dystrophin levels at six months and elicited functional improvements that are the "best ever" for this treatment class, Stifel analysts said. December 8, 2025 The FDA does not plan on holding an advisory committee meeting for z-rostudirsen, according to Dyne. Jefferies models more than $500 million in peak sales for z-rostudirsen, calling this estimate "conservative." Oppenheimer, on the other hand, did not provide a peak forecast for the z-rostudirsen, only noting that Dyne's therapy could secure a "majority" of the $1.5 billion exon-51 DMD market. In DMD, a rare and progressive neuromuscular disorder, mutations to the dystrophin protein render it dysfunctional or completely absent. Under healthy conditions, dystrophin plays a crucial role in maintaining the structure and function of muscles. Z-rostudirsen works by restoring the expression of near-full-length dystrophin, in turn restoring the function of the protein. A key player in the DMD space is Sarepta, which aside from Exondys owns the gene therapy Elevidys. Last year, two patients died after receiving Elevidys, which ultimately forced the FDA to slap a boxed warning on the product's label and limited its use to ambulatory patients four years and up. Sarepta also owns Amondys 45 and Vyondys 53 - both exon-skipping drugs like Exondys - which in November 2025 failed to elicit significant motor function improvements in the confirmatory Phase 3 ESSENCE study. Sarepta has nevertheless pushed for full approval of these products, with the FDA setting a decision date of Feb. 28, 2027. Sarepta Therapeutics is seeking to convert the accelerated approval of its therapeutic exon-skippers for Duchenne muscular dystrophy to full despite the drugs' failure to improve motor function in a confirmatory trial. July 1, 2026
Dyne Therapeutics announces a $300 million public offering of common stock to support its neuromuscular disease programs.Quiver AI SummaryDyne Therapeutics, Inc. has announced the commencement of an underwritten public offering of $300 million in shares of its common stock, with a potential additional sale of $45 million if underwriters exercise their option. The shares will be sold by Dyne, and the offering is being managed by Morgan Stanley, Je
Dyne Therapeutics completes $230 million public offering of 27.8 million shares to advance neuromuscular disease therapies. |